Evidence map›Paper›PMID 19186176›Full record

ReviewExperimental and molecular pathology2009

Nanoparticle-based targeted drug delivery.

Rajesh Singh, James W Lillard

Abstract readReview
In one paragraph

Review in Experimental and molecular pathology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 673 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
673citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

673 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article

613 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Rajesh SinghDepartment of Microbiology and Immunology, James Graham Brown Cancer Center, University of Louisville School of Medicine, Louisville, KY 40202, USA.
James W Lillard

Funding

TRANSCRIPTION FACTORS AND PROSTATE CANCERG12RR003034 · NCRR · MOREHOUSE SCHOOL OF MEDICINE · PI LIU, DONG · 1986 to 2011
$32.4M
Vascular Cell Apoptosis: Mediator Role of Transforming Growth Factor-beta-1S06GM008248 · NIGMS · MOREHOUSE SCHOOL OF MEDICINE · PI HE, QING · 1989 to 2009
$19.8M
BIOMARKER VALIDATION LABORATORIESU24CA086359 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI GRIZZLE, WILLIAM E. · 2000 to 2010
$5.1M
The Grady Center for Health DisparitiesP60MD000525 · NIMHD · EMORY UNIVERSITY · PI LIPSCOMB, JOSEPH · 2003 to 2006
$3.7M
Morehouse School of Medicine/UAB Cancer Ctr PartnershipU56CA092078 · NCI · MOREHOUSE SCHOOL OF MEDICINE · PI OKOLI, JOEL · 2001 to 2005
$2.2M
Role of RANTES in Pneumococcal ImmunopathogenesisR01AI057808 · NIAID · UNIVERSITY OF LOUISVILLE · PI LILLARD, JAMES W · 2004 to 2007
$1.1M
ROLE OF CHEMOKINES IN T CELL MEDIATED COLITISR03DK058967 · NIDDK · MOREHOUSE SCHOOL OF MEDICINE · PI LILLARD, JAMES W · 2000 to 2002
$212k
NCI NIH HHS CA086359NCI NIH HHS CA092078NCI NIH HHS U24 CA086359NCI NIH HHS U56 CA092078NCRR NIH HHS G12 RR003034NCRR NIH HHS RR03034NIAID NIH HHS AI057808NIAID NIH HHS R01 AI057808NIDDK NIH HHS DK58967NIDDK NIH HHS R03 DK058967NIGMS NIH HHS GM08248NIGMS NIH HHS GM09248NIGMS NIH HHS S06 GM008248NIMHD NIH HHS MD00525NIMHD NIH HHS P60 MD000525
6 · The paper itself

Abstract

Nanotechnology could be defined as the technology that has allowed for the control, manipulation, study, and manufacture of structures and devices in the "nanometer" size range. These nano-sized objects, e.g., "nanoparticles", take on novel properties and functions that differ markedly from those seen from items made of identical materials. The small size, customized surface, improved solubility, and multi-functionality of nanoparticles will continue to open many doors and create new biomedical applications. Indeed, the novel properties of nanoparticles offer the ability to interact with complex cellular functions in new ways. This rapidly growing field requires cross-disciplinary research and provides opportunities to design and develop multifunctional devices that can target, diagnose, and treat devastating diseases such as cancer. This article presents an overview of nanotechnology for the biologist and discusses the attributes of our novel XPclad((c)) nanoparticle formulation that has shown efficacy in treating solid tumors, single dose vaccination, and oral delivery of therapeutic proteins.

Indexed as

AnimalsAntineoplastic AgentsDendrimersDrug Delivery SystemsHumansHydrogelsLiposomesMicellesNanoparticlesNanotechnologyNeoplasmsQuantum DotsAntineoplastic AgentsDendrimersHydrogelsLiposomesMicelles

Identifiers

PMID19186176
PMCPMC3249419

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.